Indiana-based pharmaceutical giant Eli Lilly has secured exclusive worldwide rights to a groundbreaking gene therapy, AAV-AIPL1, targeting Leber congenital amaurosis 4 (LCA4). LCA4 is a rare genetic disorder that causes severe visual impairment from birth and accounts for approximately 20% of all blindness in children who are legally blind.
Under the terms of the agreement, UK-based biotech firm MeiraGTx will receive an upfront payment of $75 million, with the potential to earn up to $400 million more in milestone-based payments as the therapy progresses toward regulatory approval. In addition to AAV-AIPL1, Lilly gains access to MeiraGTx’s broader portfolio of gene therapy technologies for pre-defined ophthalmology targets.
“This agreement provides the opportunity for these innovative technologies to be used much more broadly than we have the capacity to do alone, and in that way, reaching more patients and transforming more lives,” said Zandy Forbes, CEO of MeiraGTx, in an interview with BioXconomy.
Potential for Vision Restoration
Andrew Adams, Vice President of Molecular Discovery at Eli Lilly, highlighted the company’s commitment to advancing transformative therapies for patients with severe eye diseases. “We aim to bring transformative treatments to patients around the world suffering from eye diseases, starting with AAV-AIPL1, which has shown the unprecedented ability to restore vision in children who were born legally blind,” he stated.
MeiraGTx’s Phase I clinical trial results, published in The Lancet earlier this year, have been particularly promising. Forbes explained that the trial involved 11 children with LCA4 caused by mutations in the AIPL1 gene. All participants were born blind. Remarkably, when treated before the age of four, 100% of the children gained measurable vision. “This data is unprecedented,” Forbes said. “No further studies are being conducted prior to filing with the Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA).”
Strategic Focus on Ophthalmology
Lilly’s recent activities underscore a growing interest in retinal disease therapies. Just last month, the company acquired Adverum Biotechnologies for $261.7 million, gaining access to its lead gene therapy candidate, Ixoberogene soroparvovec, aimed at treating vision loss. Adams emphasized that ophthalmology is “an emerging area of interest” for the pharmaceutical company, reflecting Lilly’s broader strategy to develop next-generation treatments using advanced genetic technologies.
Forbes added, “Lilly is clearly a company with a great interest in using the most advanced technologies to develop the new treatment modalities of the future, in particular, genetic medicines. We are excited that a company such as Lilly, focused on bringing advancements in science to patients globally, has chosen to license our technologies in genetic medicine.”
Broader Implications for Gene Therapy
The licensing agreement extends beyond AAV-AIPL1, providing Lilly with strategic access to MeiraGTx’s gene therapy platforms, potentially enabling future treatments for additional ophthalmic disorders. The deal exemplifies a growing trend among large pharmaceutical companies to invest in precision therapies for rare diseases, leveraging small biotech innovations to accelerate development and commercialization.
Conclusion
The AAV-AIPL1 licensing deal marks a major milestone in the advancement of gene therapies for congenital blindness. With regulatory filings planned in both the UK and the US, the therapy has the potential to redefine treatment options for children born with LCA4. Combined with Lilly’s broader investments in ophthalmology and AI-enabled drug discovery, the company is positioning itself at the forefront of innovative solutions for previously untreatable conditions.
Related topics
